10
Participants
Start Date
June 27, 2023
Primary Completion Date
July 1, 2027
Study Completion Date
December 1, 2027
Afatinib
Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
Dasatinib
Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
Palbociclib
Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
Everolimus
Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
Olaparib
Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
RECRUITING
Arthur J.E. Child Comprehensive Cancer Centre, Calgary
Tom Baker Cancer Centre
OTHER
AHS Cancer Control Alberta
OTHER